Gene fusions are vital biomarkers for tumor diagnosis and drug development, with precise detection becoming increasingly ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

An AI tool analyzes biopsy images. To determine the type and severity of cancer, pathologists typically examine thin slices ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

About two years ago, Katie Bruckmann joined the Covid club when she became infected with the virus for the very first time.

histological subtype was not correlated with survival independently of the fusion gene The collaborative study ... of Institut Curie and the Institute of Cancer Research, respectively.

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...